Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Goldstein, 2001, Familial hypercholesterolemia, 2863 Rader, 2003, Monogenic hypercholesterolemia: new insights in pathogenesis and treatment, J Clin Invest, 111, 1795, 10.1172/JCI200318925 Gagne, 2002, Efficacy and safety of ezetimibe co administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia, Circulation, 105, 2469, 10.1161/01.CIR.0000018744.58460.62 Sachais, 2005, Long-term effects of LDL apheresis in patients with severe hypercholesterolemia, J Clin Apher, 20, 252, 10.1002/jca.20036 Thompson, 2008, Recommendations for the use of LDL apheresis, Atherosclerosis, 198, 247, 10.1016/j.atherosclerosis.2008.02.009 Moghadasian, 2001, Surgical management of dyslipidemia: clinical and experimental evidence, J Invest Surg, 14, 71, 10.1080/08941930152024183 Lopez-Santamaria, 2000, Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to-side portacaval shunt and ileal bypass, J Pediatr Surg, 35, 630, 10.1053/jpsu.2000.0350630 Davis, 1999, Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver, Biochim Biophys Acta, 1440, 1, 10.1016/S1388-1981(99)00083-9 Cuchel, 2007, Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia, N Engl J Med, 356, 148, 10.1056/NEJMoa061189 Samaha, 2008, Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia, Nat Clin Pract Cardiovasc Med, 5, 497, 10.1038/ncpcardio1250 Stein, 2009, Other therapies for reducing low-density lipoprotein cholesterol: medication in development, Endocrin Metab Clin N Am, 38, 99, 10.1016/j.ecl.2008.11.011 Crooke, 2007, Cardiovascular therapeutic applications, 601 Crooke, 2005, An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis, J Lipid Res, 4, 872, 10.1194/jlr.M400492-JLR200 Kastelein, 2006, Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B, Circulation, 114, 1729, 10.1161/CIRCULATIONAHA.105.606442 Yu, 2009, Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100, Biochem Pharmacol, 77, 910, 10.1016/j.bcp.2008.11.005 Akdim F, Stroes ESG, Sijbrands EJG, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects on stable statin therapy. J Am Coll Cardiol (in press). Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density-lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol (in press). 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 Fishbein, 2005, Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound, J Clin Gastroenterol, 39, 619, 10.1097/00004836-200508000-00012 Yokoo, 2009, Accuracy of low-flip-angle multiecho gradient-recalled-echo MR Imaging at 1.5T, Radiology, 251, 67, 10.1148/radiol.2511080666 Björnsson, 2005, Outcome and prognostic markers in severe drug-induced liver disease, Hepatology, 42, 481, 10.1002/hep.20800 1994, Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3 2005, Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1 2009, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality, JAMA, 302, 412, 10.1001/jama.2009.1063 Maron, 2000, Current perspectives on statins, Circulation, 101, 207, 10.1161/01.CIR.101.2.207 Abbott, 1988, High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction, Arteriosclerosis, 8, 207, 10.1161/01.ATV.8.3.207 Cannon, 2004, Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583 Ridker, 2009, Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial, Lancet, 373, 1175, 10.1016/S0140-6736(09)60447-5 Visser, 2009, Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia, J Lipid Res Rayburn, 2008, Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible, Drug Discov Today, 13, 513, 10.1016/j.drudis.2008.03.014